Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5622807 | 0.98 | KCNH2 (0.41) | KCNH2MAOAMAOBHTR2AGRIK1 | |
| SCHEMBL8631288 | 0.82 | KCNH2 (0.50) | KCNH2MAOAMAOBHTR2AGRIK1 | |
| SCHEMBL7022054 | 0.80 | MAOA (0.52) | KCNH2MAOAMAOBHTR2ASIGMAR1 | |
| SCHEMBL10345872 | 0.80 | MAOA (0.52) | KCNH2MAOAMAOBHTR2ASIGMAR1 | |
| SCHEMBL3334933 | 0.80 | SIGMAR1 (0.52) | MAOAMAOBHTR2ASIGMAR1IDO1 | |
| SCHEMBL7451119 | 0.79 | S1PR2 (0.51) | KCNH2MAOAMAOBHTR2ASIGMAR1 | |
| SCHEMBL855071 | 0.78 | ANPEP (0.50) | KCNH2HTR2A | |
| SCHEMBL5924988 | 0.78 | ANPEP (0.50) | KCNH2HTR2A | |
| SCHEMBL8067078 | 0.78 | ANPEP (0.50) | KCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL9635016 | 0.76 | ANPEP (0.48) | KCNH2MAOAMAOBHTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | disclosed |
| WO-2002032871-A2 | COMPOUNDS AND METHODS FOR TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | KCNH2 1507/4885MAOA 1273/4885MAOB 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.